(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 3.88% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.88%.
Phibro Animal Health's revenue in 2026 is $1,500,043,000.On average, 7 Wall Street analysts forecast PAHC's revenue for 2027 to be $64,051,686,564, with the lowest PAHC revenue forecast at $60,968,768,148, and the highest PAHC revenue forecast at $66,282,745,944. On average, 6 Wall Street analysts forecast PAHC's revenue for 2028 to be $66,161,051,796, with the lowest PAHC revenue forecast at $62,956,439,232, and the highest PAHC revenue forecast at $68,919,452,484.
In 2029, PAHC is forecast to generate $68,189,287,596 in revenue, with the lowest revenue forecast at $65,512,016,340 and the highest revenue forecast at $70,176,958,680.